Rule 3.19A.2
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity QRxPharma Limited |
ABN 16 102 254 151 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director | Bruce Hancox |
Date of last notice | 14 July 2014 |
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest | Indirect |
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | HSF1 Pty Ltd as trustee for the HSF1 Superannuation Fund (member) |
Date of change | 28 May 2015 |
No. of securities held prior to change | 740,000 shares (indirect interest) |
Class | Fully paid ordinary shares |
Number acquired | N/A |
Number disposed | Cessation of an indirect interest in 740,000 shares |
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Consideration: $12,580 paid as entitlement under superannuation fund |
No. of securities held after change | Nil shares (indirect interest) |
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y Change of Director's Interest NoticeNature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | The change is the cessation of an indirect interest previously held through membership of HSF1 Superannuation Fund and directorship of HSF1 Pty Ltd, the trustee of that fund. On 28 May 2015, Bruce Hancox ceased to be a member of that superannuation fund and ceased to be a director of the trustee of that fund. |
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract | N/A |
Nature of interest | N/A |
Name of registered holder (if issued securities) | N/A |
Date of change | N/A |
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
Interest acquired | N/A |
Interest disposed | N/A |
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
Interest after change | N/A |
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
If prior written clearance was provided, on what date was this provided? | N/A |
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 01/01/2011
QRxpharma Ltd. published this content on 26 May 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 May 2016 05:30:07 UTC.
Original documenthttp://www.qrxpharma.com/irm/PDF/1515/ChangeofDirectorsInterestNoticeBruceHancox
Public permalinkhttp://www.publicnow.com/view/7C99D9A982946A7809E633901C40C99E1B4094FC